-+ 0.00%
-+ 0.00%
-+ 0.00%

12 Health Care Stocks Moving In Tuesday's After-Market Session

Benzinga·03/18/2025 21:05:47
Listen to the news

Gainers

  • Virpax Pharmaceuticals (NASDAQ:VRPX) shares moved upwards by 28.9% to $0.17 during Tuesday's after-market session. The company's market cap stands at $3.0 million.
  • Cargo Therapeutics (NASDAQ:CRGX) shares increased by 19.99% to $4.56. The market value of their outstanding shares is at $209.9 million. As per the news, the Q4 earnings report came out 4 days ago.
  • Adagio Medical Holdings (NASDAQ:ADGM) shares rose 14.88% to $1.09. The company's market cap stands at $16.7 million.
  • Pulmatrix (NASDAQ:PULM) shares moved upwards by 12.02% to $8.29. The company's market cap stands at $30.2 million.
  • OmniAb (NASDAQ:OABI) shares increased by 8.46% to $3.46. The market value of their outstanding shares is at $418.7 million. As per the news, the Q4 earnings report came out today.
  • Scienture Holdings (NASDAQ:SCNX) stock increased by 6.91% to $1.7. The company's market cap stands at $14.6 million.

Losers

  • HealthEquity (NASDAQ:HQY) stock fell 12.3% to $89.15 during Tuesday's after-market session. The market value of their outstanding shares is at $7.7 billion. As per the news, the Q4 earnings report came out today.
  • Regencell Bioscience (NASDAQ:RGC) shares decreased by 10.57% to $28.26. The company's market cap stands at $367.7 million.
  • Rallybio (NASDAQ:RLYB) stock declined by 9.6% to $0.7. The market value of their outstanding shares is at $29.0 million. The company's, Q4 earnings came out 3 days ago.
  • Exicure (NASDAQ:XCUR) stock declined by 7.26% to $11.5. The company's market cap stands at $34.9 million.
  • Absci (NASDAQ:ABSI) stock declined by 7.1% to $2.88. The company's market cap stands at $330.7 million. As per the press release, Q4 earnings came out today.
  • Savara (NASDAQ:SVRA) stock decreased by 6.63% to $2.62. The market value of their outstanding shares is at $449.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.